Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.2900
-0.0166 (-5.41%)
At close: Apr 24, 2026, 4:00 PM EDT
0.2990
+0.0090 (3.10%)
After-hours: Apr 24, 2026, 7:34 PM EDT
Mereo BioPharma Group Stock Forecast
MREO's stock price has decreased by -88.67% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Mereo BioPharma Group stock have a consensus rating of "Buy" and an average price target of $1.50, which forecasts a 417.24% increase in the stock price over the next year. The lowest target is $0.50 and the highest is $3.00.
Price Target: $1.50 (+417.24%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 16, 2026.
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 23, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $1 | Strong Buy | Reiterates | $1 | +244.83% | Jan 16, 2026 |
| Needham | Needham | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +934.48% | Jan 13, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $7 → $0.5 | Strong Buy → Hold | Downgrades | $7 → $0.5 | +72.41% | Dec 30, 2025 |
| BTIG | BTIG | Strong Buy Maintains $6 → $1 | Strong Buy | Maintains | $6 → $1 | +244.83% | Dec 29, 2025 |
Financial Forecast
Revenue This Year
26.42M
from 500.00K
Increased by 5,184.20%
Revenue Next Year
41.09M
from 26.42M
Increased by 55.51%
EPS This Year
-0.03
from -0.26
EPS Next Year
-0.00
from -0.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 52.5M | 109.9M | ||||||
| Avg | 26.4M | 41.1M | ||||||
| Low | n/a | 303,800 |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10,400.0% | 315.9% | ||||||
| Avg | 5,184.2% | 55.5% | ||||||
| Low | - | -98.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.02 | 0.13 | ||||||
| Avg | -0.03 | -0.00 | ||||||
| Low | -0.06 | -0.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.